PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Under the Remarkork Reduction Act of 1995, no persons are required to respond to a collection of attendance transfer that the contract of the					
Substitute for form 1449A/PTO				Complete if Known		
				Application Number	09/837,446	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	April 17, 2001	
				First Named Inventor	BUTCHER, EUGENE C.	
				Art Unit	1646	
				Examiner Name	MERTZ, PREMA MARIA	
Sheet	1	of	1	Attorney Docket Number	STAN-110CON	
O11001	•	1	· ·			

			U.S. PATENT	DOCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PM		US- 5,932,703	Aug. 3, 1999	GODISKA et al.	
		US-			
		US-			

		FOREIG	N PATENT DO	CUMENTS		
Examiner Initials'	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	No.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Applicant of Cited Document		
PM		WO 96/40923	12-19-1996	GODISKA et al.		
PM		WO 00/42074	07-20-2000	WU et al.		
	·	OTHER ART-NON	PATENT LITER	ATURE DOCUMENTS		,
Examiner Initials*	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),				
PM	ANDREW et al., STCP-1 (MDC) CC CHEMOKINE ACTS SPECIFICALLY ON CHRONICALLY ACTIVATED TH2 LYMPHOCYTES AND IS PRODUCED BY MONOCYTES ON STIMULATION WITH TH2 CYTOKINES IL-4 AND IL-13, J. of Immunology, 1998, 5027-5038					
PM		CAMPBELL et al., THE RECOGNITION BY CUTAN Nature, 1999, 400: 776-780	CHEMOKINE EOUS BUT N	RECEPTOR CCR NOT INTESTINAL M	4 IN VASCULAR EMORY T CELLS,	

Examiner P	Mart	Date Considered 11 4 00	4
Signature Common /	leng	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.